Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 24;12(6):1681.
doi: 10.3390/cancers12061681.

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

Nicola Silvestris  1   2 , Oronzo Brunetti  1 , Alessandro Bittoni  3 , Ivana Cataldo  4 , Domenico Corsi  5 , Stefano Crippa  6 , Mirko D'Onofrio  7 , Michele Fiore  8 , Elisa Giommoni  9 , Michele Milella  10 , Raffaele Pezzilli  11 , Enrico Vasile  12 , Michele Reni  13
Affiliations
Review

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

Nicola Silvestris et al. Cancers (Basel). .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

Keywords: diagnosis; follow-up; guidelines; pancreatic ductal adenocarcinoma; recommendations; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. AIRTUM Working Group: I numeri del Cancro in Italia 2019. Pancreas Esocrino. [(accessed on 25 March 2019)];2019 :169–172. Available online: https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operat....
    1. Alavanja M., Baron J.A., Brownson R.J., Buffler P.A., DeMarini D.M., Djordjevic M.V., Doll R., Fontham E.T.H., Gao Y.T., Gray N., et al. Tobacco Smoke and Involuntary Smoking. Vol. 83 IARC; Lyon, France: 2004. IARC Monographs in the evaluation of the carcinogenic risk to humans. - PMC - PubMed
    1. Arslan A.A., Helzlsouer K.J., Kooperberg C., Shu X.O., Steplowski E., Bueno-de-Mesquita H.B., Fuchs C.S., Gross M.D., Jacobs E.J., Lacroix A.Z., et al. Anthropometric measures, body mass index and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) Arch. Intern. Med. 2010;170:791–802. doi: 10.1001/archinternmed.2010.63. - DOI - PMC - PubMed
    1. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO Classification of Tumours of the Digestive System. 4th ed. WHO-IARC; Lyon, France: 2010.
    1. Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am. Soc. Clin. Oncol. Educ. Book. 2019;39:79–86. doi: 10.1200/EDBK_238977. - DOI - PubMed

LinkOut - more resources